What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug?
Truist analyst Gregory Renza downgraded Exelixis (EXEL) to Hold from Buy, raising his price target to $54 from $51. The change followed his resumption of coverage and cited pipeline uncertainty around zanzalintinib. The FDA is reviewing a zanzalintinib plus atezolizumab application for metastatic colorectal cancer, supported by Phase 3 STELLAR-303 data.
How this was made
The 30-second read
Why it matters
The key new tradable element is the rating change tied to zanzalintinib pipeline uncertainty, despite ongoing FDA review for metastatic colorectal cancer.
Market read
A fresh sell-side risk reset (Hold vs Buy) highlights that regulatory review progress may not be enough without additional clinical data readouts.
What to watch
The article doesn’t quantify how material pending readouts are to valuation; traders may need to assess whether the market already priced in pipeline uncertainty versus the incremental impact of the downgrade.
Background
Truist resumed coverage via analyst Gregory Renza and downgraded Exelixis to Hold, replacing a prior consistently bullish stance from Asthika Goonewardene.
Ticker impact
Truist downgraded Exelixis to Hold from Buy, citing pipeline uncertainty around zanzalintinib and pending clinical readouts.
Near-term downside bias versus prior Buy stance; magnitude likely limited unless new zanzalintinib readouts materially de-risk the program.
A Hold downgrade with a modest PT change (54 vs 51) is a real sentiment/risk reset, but the article provides no new trial/regulatory decision beyond describing the FDA review and pending readouts.
Market effects
Reinforces biotech/oncology risk framing: even with Phase 3 support and FDA review, investors may discount commercial odds until additional readouts land.
No specific regional catalyst beyond US-listed analyst action.
Limited; story is company-specific and tied to US FDA review timing.
Counterpoint
The Hold is driven by uncertainty, but the FDA is actively reviewing the zanzalintinib/atezolizumab application supported by Phase 3 STELLAR-303 data—approval could still re-rate the risk profile.
Key entities
- companyExelixis, Inc.
Oncology biotech developing cabozantinib (Cabometyx) and zanzalintinib as a next-generation candidate.
- analystTruist analyst Gregory Renza
Downgraded EXEL to Hold from Buy and set a $54 price target, citing pipeline uncertainty.
- drug_programzanzalintinib
Next-generation cancer drug candidate under FDA review in combination with atezolizumab for previously treated metastatic colorectal cancer.
